Jaeger H, Knechten H, Moll A, Weitner L, Fischer H, Schmitt-Rau K; International Conference on AIDS.
Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. ThPeB7352.
KIS, Munich, Germany
BACKGROUND: Recombinant human growth hormone (r-hGH) has demonstrated efficacy in treating HAW. HAW has become less prominent since the introduction of highly active antiretroviral therapy (HAART). Recent studies suggest that patients receiving HAART may still experience HAW. We investigated the efficacy of r-hGH in these patients. METHODS: We treated 27 HIV-positive patients receiving HAART who had either recent loss of </=5% body weight or weight </=90% lower limit of normal with 12 weeks of r-hGH (6 mg given either daily or every other day). Body composition changes were monitored using bioelectrical impedance analysis (BIA). Results were assessed for all patients and for a subgroup meeting more stringent definitions of wasting (BIA phase angle [alpha] </=5.6˚, n=14). RESULTS: Significant increases from baseline in weight and body cell mass (BCM) occurred in the full population (medians: 2.0 kg weight, 1.5 kg BCM, whereas body fat decreased significantly by 1.9 kg. Patients with phase angle [alpha] </=5.6˚ showed following results: (medians) 2.5 kg weight, 1.95 kg BCM, -1 kg fat, and also showed improvements in the ratio of extracellular mass (ECM) to BCM. At 8 weeks follow-up there was a trend towards loss of the weight and BCM gained on treatment. Treatment was well tolerated. CONCLUSION: Overall, efficacy and tolerability of r-hGH in patients with HAW were confirmed. Patients receiving HAART continue to experience wasting, and respond well to r-hGH therapy. The increases observed in weight and BCM as well as the decrease in fat compare very well to the results in the only double blind placebo controlled study conducted so far.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- Body Composition
- Body Weight
- Drug Therapy, Combination
- Electric Impedance
- HIV Infections
- HIV Seropositivity
- Human Growth Hormone
- Humans
- Nutritional Status
- drug therapy
- therapy
Other ID:
UI: 102256744
From Meeting Abstracts